1997 update of recommendations for the use of tumor markers in breast and colorectal cancer

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 793-795

  Bast, Robert C ^a   Desch, Christopher E ^a   Hayes, Daniel F ^a   Kemeny, Nancy E ^a   Ravdin, Peter ^a   Somerfield, Mark R ^a   Smith, Thomas J ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; PROTEIN P53; SIALIC ACID; TUMOR MARKER;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; COST BENEFIT ANALYSIS; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0031916321     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.793     Document Type: Review

References (3)

1. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
2. Chan DW, Beveridge RA, Hyman M, et al: Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322-2328, 1997
3. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996